Reprogramming human gallbladder cells into insulin-producing β-like cells.

Area of Science:

• Cell Biology
• Developmental Biology
• Endocrinology

Background:

• Gallbladder and cystic duct (GBCs) are extrahepatic biliary structures with a shared developmental origin with the ventral pancreas.
• Type 1 diabetes (T1D) necessitates effective cell replacement therapies to restore insulin production.

Purpose of the Study:

• To investigate the potential of human GBCs as a source for autologous cell replacement therapy for T1D.
• To develop a method for genetic reprogramming of GBCs into functional insulin-producing beta-like cells.

Main Methods:

• Large-scale expansion of patient-derived human GBCs ex vivo.
• Adenoviral-mediated co-expression of transcription factors (PDX1, MAFA, NEUROG3, PAX6) to induce pancreatic endocrine fate.
• In vitro differentiation culture and enrichment using an islet-specific surface marker.
• Engraftment studies in immunodeficient mice.
• Global mRNA, microRNA, and protein expression analyses.

Main Results:

• Successfully reprogrammed human GBCs (rGBCs) into insulin-producing, glucose-responsive beta-like cells.
• rGBCs expressed key pancreatic endocrine genes and an islet-specific surface marker.
• rGBCs demonstrated successful engraftment in vivo.
• Identified potential regulators of biliary-to-beta cell fate conversion.

Conclusions:

• Human GBCs can be reliably reprogrammed into functional beta-like cells ex vivo.
• The gallbladder represents a promising, accessible source for reprogrammable cells for autologous T1D cell therapy.
• This study establishes a novel platform for diabetes cell therapy development.